Titan Pharmaceuticals, Inc. (TTNP)
USD 3.6
(-1.66%)
USD 3.6
(-1.66%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.46 Million USD | -28.62% |
| 2022 | 10.29 Million USD | -3.61% |
| 2021 | 10.68 Million USD | -8.84% |
| 2020 | 11.71 Million USD | -38.87% |
| 2019 | 19.16 Million USD | 40.55% |
| 2018 | 13.63 Million USD | -7.34% |
| 2017 | 14.71 Million USD | 37.26% |
| 2016 | 10.72 Million USD | 27.19% |
| 2015 | 8.43 Million USD | 18.38% |
| 2014 | 7.12 Million USD | -37.38% |
| 2013 | 11.37 Million USD | -26.57% |
| 2012 | 15.48 Million USD | 6.26% |
| 2011 | 14.57 Million USD | -9.58% |
| 2010 | 16.11 Million USD | 173.46% |
| 2009 | 5.89 Million USD | -77.32% |
| 2008 | 25.99 Million USD | 40.81% |
| 2007 | 18.45 Million USD | 12.0% |
| 2006 | 16.47 Million USD | -28.79% |
| 2005 | 23.14 Million USD | -9.79% |
| 2004 | 25.65 Million USD | -6.27% |
| 2003 | 27.36 Million USD | -21.57% |
| 2002 | 34.89 Million USD | 21.49% |
| 2001 | 28.72 Million USD | 36.71% |
| 2000 | 21.01 Million USD | 66.75% |
| 1999 | 12.6 Million USD | 6.78% |
| 1998 | 11.8 Million USD | -54.09% |
| 1997 | 25.7 Million USD | 125.44% |
| 1996 | 11.4 Million USD | 16.33% |
| 1995 | 9.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.07 Million USD | 95.48% |
| 2024 Q1 | 1.06 Million USD | -44.97% |
| 2023 Q1 | 1.69 Million USD | -36.25% |
| 2023 Q4 | 1.92 Million USD | -6.45% |
| 2023 Q2 | 1.58 Million USD | -6.36% |
| 2023 Q3 | 2.06 Million USD | 29.7% |
| 2023 FY | 7.34 Million USD | -28.62% |
| 2022 Q2 | 2.59 Million USD | -5.09% |
| 2022 Q4 | 2.66 Million USD | 0.57% |
| 2022 Q3 | 2.64 Million USD | 2.12% |
| 2022 FY | 10.29 Million USD | -3.61% |
| 2022 Q1 | 2.73 Million USD | 4.08% |
| 2021 Q2 | 2.68 Million USD | -16.32% |
| 2021 Q1 | 3.2 Million USD | 175.11% |
| 2021 Q3 | 2.17 Million USD | -18.99% |
| 2021 Q4 | 2.62 Million USD | 20.81% |
| 2021 FY | 10.68 Million USD | -8.84% |
| 2020 Q4 | -4.26 Million USD | -183.47% |
| 2020 Q3 | 5.11 Million USD | -6.75% |
| 2020 FY | 11.71 Million USD | -38.87% |
| 2020 Q2 | 5.48 Million USD | 1.67% |
| 2020 Q1 | 5.39 Million USD | 20.85% |
| 2019 Q4 | 4.46 Million USD | -3.9% |
| 2019 Q1 | 4.92 Million USD | 40.5% |
| 2019 FY | 19.16 Million USD | 40.55% |
| 2019 Q2 | 5.13 Million USD | 4.3% |
| 2019 Q3 | 4.64 Million USD | -9.65% |
| 2018 FY | 13.63 Million USD | -7.34% |
| 2018 Q2 | 3.23 Million USD | -6.74% |
| 2018 Q1 | 3.47 Million USD | 1.14% |
| 2018 Q4 | 3.5 Million USD | 2.39% |
| 2018 Q3 | 3.42 Million USD | 5.78% |
| 2017 Q3 | 4.11 Million USD | 11.14% |
| 2017 FY | 14.71 Million USD | 37.26% |
| 2017 Q4 | 3.43 Million USD | -16.5% |
| 2017 Q1 | 3.47 Million USD | 5.72% |
| 2017 Q2 | 3.69 Million USD | 6.36% |
| 2016 Q1 | 1.83 Million USD | -18.62% |
| 2016 Q3 | 2.64 Million USD | -10.74% |
| 2016 FY | 10.72 Million USD | 27.19% |
| 2016 Q4 | 3.28 Million USD | 24.49% |
| 2016 Q2 | 2.96 Million USD | 61.66% |
| 2015 Q3 | 1.8 Million USD | -2.7% |
| 2015 Q1 | 2.52 Million USD | 16.67% |
| 2015 Q4 | 2.25 Million USD | 24.86% |
| 2015 FY | 8.43 Million USD | 18.38% |
| 2015 Q2 | 1.85 Million USD | -26.68% |
| 2014 Q3 | 1.64 Million USD | 12.87% |
| 2014 Q2 | 1.46 Million USD | -20.81% |
| 2014 Q1 | 1.84 Million USD | 18.8% |
| 2014 Q4 | 2.16 Million USD | 31.29% |
| 2014 FY | 7.12 Million USD | -37.38% |
| 2013 FY | 11.37 Million USD | -26.57% |
| 2013 Q4 | 1.55 Million USD | -33.23% |
| 2013 Q3 | 2.32 Million USD | -6.59% |
| 2013 Q2 | 2.49 Million USD | -50.23% |
| 2013 Q1 | 5 Million USD | 35.22% |
| 2012 FY | 15.48 Million USD | 6.26% |
| 2012 Q4 | 3.7 Million USD | -4.76% |
| 2012 Q3 | 3.88 Million USD | 25.36% |
| 2012 Q2 | 3.09 Million USD | -35.46% |
| 2012 Q1 | 4.8 Million USD | 120.38% |
| 2011 FY | 14.57 Million USD | -9.58% |
| 2011 Q2 | 4.89 Million USD | 8.03% |
| 2011 Q3 | 2.96 Million USD | -39.35% |
| 2011 Q4 | 2.17 Million USD | -26.61% |
| 2011 Q1 | 4.53 Million USD | -32.47% |
| 2010 Q4 | 6.71 Million USD | 79.65% |
| 2010 FY | 16.11 Million USD | 173.46% |
| 2010 Q3 | 3.73 Million USD | 21.74% |
| 2010 Q2 | 3.06 Million USD | 17.77% |
| 2010 Q1 | 2.6 Million USD | 82.17% |
| 2009 Q3 | 1.58 Million USD | -10.4% |
| 2009 Q4 | 1.43 Million USD | -9.78% |
| 2009 FY | 5.89 Million USD | -77.32% |
| 2009 Q1 | 1.11 Million USD | -81.8% |
| 2009 Q2 | 1.76 Million USD | 59.37% |
| 2008 Q4 | 6.1 Million USD | 1.36% |
| 2008 FY | 25.99 Million USD | 40.81% |
| 2008 Q1 | 6.01 Million USD | -5.71% |
| 2008 Q2 | 7.86 Million USD | 30.71% |
| 2008 Q3 | 6.01 Million USD | -23.45% |
| 2007 FY | 18.45 Million USD | 12.0% |
| 2007 Q4 | 6.37 Million USD | 39.89% |
| 2007 Q3 | 4.56 Million USD | 13.29% |
| 2007 Q2 | 4.02 Million USD | 15.23% |
| 2007 Q1 | 3.49 Million USD | 0.0% |
| 2006 Q2 | 3.61 Million USD | -25.0% |
| 2006 Q1 | 4.82 Million USD | 12.67% |
| 2006 Q4 | 3.49 Million USD | -23.25% |
| 2006 FY | 16.47 Million USD | -28.79% |
| 2006 Q3 | 4.55 Million USD | 25.89% |
| 2005 Q1 | 6.46 Million USD | -10.64% |
| 2005 Q4 | 4.27 Million USD | -34.59% |
| 2005 FY | 23.14 Million USD | -9.79% |
| 2005 Q3 | 6.54 Million USD | 11.59% |
| 2005 Q2 | 5.86 Million USD | -9.29% |
| 2004 FY | 25.65 Million USD | -6.27% |
| 2004 Q2 | 5.71 Million USD | -11.8% |
| 2004 Q4 | 7.23 Million USD | 16.14% |
| 2004 Q1 | 6.48 Million USD | -5.39% |
| 2004 Q3 | 6.22 Million USD | 8.9% |
| 2003 Q3 | 6.5 Million USD | -7.02% |
| 2003 Q4 | 6.85 Million USD | 5.37% |
| 2003 FY | 27.36 Million USD | -21.57% |
| 2003 Q2 | 6.99 Million USD | -0.47% |
| 2003 Q1 | 7.02 Million USD | -25.05% |
| 2002 Q2 | 8.31 Million USD | -4.44% |
| 2002 Q1 | 8.69 Million USD | 2.08% |
| 2002 Q4 | 9.37 Million USD | 10.06% |
| 2002 FY | 34.89 Million USD | 21.49% |
| 2002 Q3 | 8.51 Million USD | 2.48% |
| 2001 Q4 | 8.51 Million USD | 20.53% |
| 2001 Q3 | 7.06 Million USD | 7.88% |
| 2001 FY | 28.72 Million USD | 36.71% |
| 2001 Q2 | 6.55 Million USD | -1.41% |
| 2001 Q1 | 6.64 Million USD | 7.26% |
| 2000 Q2 | 4.05 Million USD | -18.67% |
| 2000 Q1 | 4.98 Million USD | 38.5% |
| 2000 FY | 21.01 Million USD | 66.75% |
| 2000 Q4 | 6.19 Million USD | 6.41% |
| 2000 Q3 | 5.82 Million USD | 43.6% |
| 1999 Q4 | 3.6 Million USD | 44.0% |
| 1999 Q3 | 2.5 Million USD | -24.24% |
| 1999 Q2 | 3.3 Million USD | 10.0% |
| 1999 Q1 | 3 Million USD | -14.29% |
| 1999 FY | 12.6 Million USD | 6.78% |
| 1998 Q1 | 2.8 Million USD | -33.33% |
| 1998 FY | 11.8 Million USD | -54.09% |
| 1998 Q2 | 2.5 Million USD | -10.71% |
| 1998 Q3 | 3 Million USD | 20.0% |
| 1998 Q4 | 3.5 Million USD | 16.67% |
| 1997 Q4 | 4.2 Million USD | 5.0% |
| 1997 Q2 | 4.3 Million USD | -67.18% |
| 1997 Q3 | 4 Million USD | -6.98% |
| 1997 FY | 25.7 Million USD | 125.44% |
| 1997 Q1 | 13.1 Million USD | 211.9% |
| 1996 Q1 | 1.8 Million USD | 118.95% |
| 1996 Q4 | 4.2 Million USD | 55.56% |
| 1996 FY | 11.4 Million USD | 16.33% |
| 1996 Q3 | 2.7 Million USD | 0.0% |
| 1996 Q2 | 2.7 Million USD | 50.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q4 | -9.5 Million USD | 0.0% |
| 1995 FY | 9.8 Million USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 97.289% |
| Alkermes plc | 996.24 Million USD | 99.251% |
| Agenus Inc. | 78.18 Million USD | 90.457% |
| Aptorum Group Limited | 10.56 Thousand USD | -70513.288% |
| Ardelyx, Inc. | 169.93 Million USD | 95.61% |
| Dyadic International, Inc. | 9.15 Million USD | 18.483% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 66.472% |
| Lantern Pharma Inc. | 17.87 Million USD | 58.266% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -10.83% |
| Novavax, Inc. | 779.12 Million USD | 99.042% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 90.796% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 90.923% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 61.578% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 74.799% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 85.956% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 98.039% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 69.305% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 80.298% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 75.753% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 91.193% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 57.261% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 95.57% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 77.194% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 95.331% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.586% |
| AlloVir, Inc. | 180.93 Million USD | 95.876% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 98.326% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 74.864% |
| Bicycle Therapeutics plc | 216.92 Million USD | 96.561% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 95.66% |
| ChromaDex Corporation | 56.37 Million USD | 86.766% |
| Chimerix, Inc. | 93.38 Million USD | 92.011% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 46.361% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 95.044% |
| CRISPR Therapeutics AG | 463.49 Million USD | 98.39% |
| Precision BioSciences, Inc. | 92.46 Million USD | 91.931% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 97.063% |
| Fortress Biotech, Inc. | 200.19 Million USD | 96.273% |
| Fortress Biotech, Inc. | 200.19 Million USD | 96.273% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 77.216% |
| ImmuCell Corporation | 9.61 Million USD | 22.422% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 95.272% |
| Immix Biopharma, Inc. | 16.14 Million USD | 53.776% |
| Incyte Corporation | 1.19 Billion USD | 99.373% |
| Innoviva, Inc. | 132.15 Million USD | 94.354% |
| IO Biotech, Inc. | 91.44 Million USD | 91.841% |
| Jaguar Health, Inc. | 42.01 Million USD | 82.242% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 95.592% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 91.152% |
| ContextLogic Inc. | 387 Million USD | 98.072% |
| MiMedx Group, Inc. | 229.72 Million USD | 96.752% |
| MEI Pharma, Inc. | 34.78 Million USD | 78.551% |
| NextCure, Inc. | 67.63 Million USD | 88.969% |
| Onconetix, Inc. | 34.9 Million USD | 78.626% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | 41.464% |
| Opthea Limited | 191.96 Million USD | 96.113% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -171.153% |
| Vaxcyte, Inc. | 468.04 Million USD | 98.406% |
| PDS Biotechnology Corporation | 43.04 Million USD | 82.667% |
| Precigen, Inc. | 84.18 Million USD | 91.137% |
| Pharming Group N.V. | 225.49 Million USD | 96.691% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 95.554% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 89.718% |
| PureTech Health plc | 144.59 Million USD | 94.84% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 94.272% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 96.957% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 69.305% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 96.737% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 75.822% |
| Acelyrin, Inc. | 422.06 Million USD | 98.232% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -57764.123% |
| Summit Therapeutics Inc. | 87.68 Million USD | 91.491% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 79.87% |
| Senti Biosciences, Inc. | 94.7 Million USD | 92.122% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 93.961% |
| Elevation Oncology, Inc. | 45.44 Million USD | 83.582% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 74.682% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -89.267% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 94.355% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 78.111% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | 11.715% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 95.885% |
| Seer, Inc. | 110.49 Million USD | 93.247% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 89.431% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 92.018% |
| ESSA Pharma Inc. | 32.13 Million USD | 76.782% |
| GlycoMimetics, Inc. | 39.28 Million USD | 81.008% |
| GT Biopharma, Inc. | 13.57 Million USD | 45.043% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 96.606% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 96.29% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 97.124% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 86.855% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 86.204% |
| Alzamend Neuro, Inc. | 9.93 Million USD | 24.922% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 98.151% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 60.584% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 85.282% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 97.127% |
| Aptose Biosciences Inc. | 52.35 Million USD | 85.749% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | 48.225% |
| Soligenix, Inc. | 7.79 Million USD | 4.288% |
| Century Therapeutics, Inc. | 56.07 Million USD | 86.694% |
| Kura Oncology, Inc. | 165.8 Million USD | 95.5% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 93.484% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | 10.314% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -200.648% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 93.072% |
| Autolus Therapeutics plc | 196.72 Million USD | 96.207% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 91.187% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 93.593% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 61.508% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 97.681% |
| GRI Bio, Inc. | 11.33 Million USD | 34.148% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -5.744% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 94.313% |
| IGM Biosciences, Inc. | 265.59 Million USD | 97.191% |
| INmune Bio, Inc. | 29.89 Million USD | 75.043% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 95.676% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 81.493% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 53.309% |
| Entero Therapeutics, Inc. | 15.74 Million USD | 52.603% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 87.985% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 93.061% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 97.294% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 97.525% |
| Verastem, Inc. | 92.08 Million USD | 91.898% |
| Abeona Therapeutics Inc. | 17.93 Million USD | 58.409% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 95.983% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 93.855% |
| Histogen Inc. | 14.27 Million USD | 47.723% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | 53.509% |
| Surrozen, Inc. | 18.55 Million USD | 59.779% |
| Organovo Holdings, Inc. | 14.91 Million USD | 49.977% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -46.575% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 87.497% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 70.909% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 84.128% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | 2.251% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 95.812% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 84.6% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 96.955% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | 51.447% |
| Apollomics, Inc. | 54.14 Million USD | 86.219% |
| Amarin Corporation plc | 272.35 Million USD | 97.261% |
| Mesoblast Limited | 5.9 Million USD | -26.415% |
| Turnstone Biologics Corp. | 78.33 Million USD | 90.476% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 96.944% |
| Synaptogenix, Inc. | 8.31 Million USD | 10.258% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | 48.848% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 97.052% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 77.615% |
| Monopar Therapeutics Inc. | 8.83 Million USD | 15.516% |
| Exelixis, Inc. | 1.58 Billion USD | 99.53% |
| Better Therapeutics, Inc. | 38.26 Million USD | 80.5% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 96.785% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 99.128% |
| NLS Pharmaceutics AG | 11.8 Million USD | 36.809% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | 7.223% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 75.124% |
| Gritstone bio, Inc. | 148.37 Million USD | 94.971% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 89.165% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | 54.395% |
| Avid Bioservices, Inc. | 25.99 Million USD | 71.299% |
| Insmed Incorporated | 949.26 Million USD | 99.214% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | 52.447% |
| MediWound Ltd. | 18.86 Million USD | 60.457% |
| OmniAb, Inc. | 83.89 Million USD | 91.107% |
| Alector, Inc. | 248.8 Million USD | 97.001% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 96.816% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 85.721% |
| Zai Lab Limited | 547.47 Million USD | 98.637% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 98.128% |
| Aura Biosciences, Inc. | 84.99 Million USD | 91.221% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 96.981% |
| Immunic, Inc. | 99.22 Million USD | 92.481% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 95.308% |
| Veracyte, Inc. | 357.93 Million USD | 97.916% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.917% |
| FibroGen, Inc. | 398.11 Million USD | 98.126% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 47.495% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -8.32% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -4.705% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.771% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 71.163% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 97.643% |
| TG Therapeutics, Inc. | 198.47 Million USD | 96.241% |
| Galecto, Inc. | 35.62 Million USD | 79.058% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 81.663% |
| Fortrea Holdings Inc. | 457.3 Million USD | 98.368% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 86.254% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 74.164% |
| XBiotech Inc. | 37.51 Million USD | 80.109% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 89.165% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 63.867% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 94.748% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 92.469% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 93.261% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 99.221% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 74.134% |
| Vaxxinity, Inc. | 56.05 Million USD | 86.689% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 98.267% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 66.555% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 93.27% |
| NexImmune, Inc. | 28.16 Million USD | 73.512% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -34.896% |
| Marker Therapeutics, Inc. | 17.89 Million USD | 58.301% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.735% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 70.694% |
| Scopus BioPharma Inc. | 11.71 Million USD | 36.312% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 94.128% |
| Ainos, Inc. | 12.95 Million USD | 42.398% |
| Pluri Inc. | 22.48 Million USD | 66.81% |
| Prothena Corporation plc | 282.4 Million USD | 97.358% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 96.27% |
| Celularity Inc. | 215.05 Million USD | 96.531% |
| Rallybio Corporation | 78.93 Million USD | 90.548% |
| Cue Biopharma, Inc. | 19.54 Million USD | 61.821% |
| MeiraGTx Holdings plc | 151.07 Million USD | 95.061% |
| Omeros Corporation | 94.75 Million USD | 92.126% |
| Humacyte, Inc. | 23.49 Million USD | 68.247% |
| Immunocore Holdings plc | 308.04 Million USD | 97.578% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -120.088% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 91.411% |
| Blueprint Medicines Corporation | 722.86 Million USD | 98.968% |
| CalciMedica, Inc. | 21.81 Million USD | 65.802% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 90.007% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 95.353% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 95.644% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 97.47% |
| Pulmatrix, Inc. | 22.03 Million USD | 66.145% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 78.421% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 91.604% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 98.647% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 89.716% |
| Cytokinetics, Incorporated | 173.61 Million USD | 95.702% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 78.323% |
| Nutriband Inc. | 5.73 Million USD | -30.118% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 82.893% |
| Vor Biopharma Inc. | 126.03 Million USD | 94.08% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 99.373% |
| Evogene Ltd. | 27.79 Million USD | 73.152% |
| ProKidney Corp. | 151.52 Million USD | 95.076% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 89.941% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | 3.006% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 98.785% |
| CorMedix Inc. | 48.95 Million USD | 84.76% |
| BioLineRx Ltd. | 50.8 Million USD | 85.314% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 95.049% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 80.403% |
| Atai Life Sciences N.V. | 125.78 Million USD | 94.068% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 90.861% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 90.835% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 97.046% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 77.211% |
| MediciNova, Inc. | 10.9 Million USD | 31.552% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 94.208% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2.775% |
| GeoVax Labs, Inc. | 6.02 Million USD | -23.892% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 98.434% |
| Biomea Fusion, Inc. | 126.13 Million USD | 94.085% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 99.431% |
| Mereo BioPharma Group plc | 35.84 Million USD | 79.184% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 96.096% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 96.755% |
| Absci Corporation | 73.66 Million USD | 89.872% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 72.95% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 94.415% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 96.919% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 97.153% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 96.413% |
| Allakos Inc. | 196.05 Million USD | 96.194% |
| Imunon, Inc. | 20.31 Million USD | 63.265% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 93.425% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 97.976% |
| BioAtla, Inc. | 129.68 Million USD | 94.247% |
| NLS Pharmaceutics AG | 11.8 Million USD | 36.809% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 52.907% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 91.214% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 82.133% |
| XOMA Corporation | 46.46 Million USD | 83.942% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 93.289% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 94.763% |
| aTyr Pharma, Inc. | 12.97 Million USD | 42.515% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 92.802% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 95.684% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 97.071% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 80.055% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | 9.287% |
| Akari Therapeutics, Plc | 16.8 Million USD | 55.605% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -228.105% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 97.507% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -10.883% |
| UroGen Pharma Ltd. | 138.88 Million USD | 94.628% |
| Sutro Biopharma, Inc. | 243 Million USD | 96.93% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2.562% |
| Orgenesis Inc. | 45.75 Million USD | 83.694% |
| Entera Bio Ltd. | 8.86 Million USD | 15.79% |
| GH Research PLC | 41.22 Million USD | 81.9% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 70.978% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 91.017% |
| Xencor, Inc. | 306.97 Million USD | 97.57% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -51.228% |
| Replimune Group, Inc. | 234.77 Million USD | 96.822% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 63.587% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 96.11% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -10.883% |
| Portage Biotech Inc. | 18.19 Million USD | 59.003% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2.775% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 92.892% |
| OncoCyte Corporation | 25.63 Million USD | 70.898% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -22.4% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | 34.879% |
| Purple Biotech Ltd. | -22.46 Million USD | 133.209% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | 54.727% |
| scPharmaceuticals Inc. | 65.17 Million USD | 88.553% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | 11.733% |
| HilleVax, Inc. | 133.34 Million USD | 94.405% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | 27.457% |
| Tharimmune, Inc. | 9.45 Million USD | 21.091% |
| Genprex, Inc. | 31.06 Million USD | 75.979% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 96.021% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 76.221% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -875.294% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -36.977% |
| OKYO Pharma Limited | 8243.57 USD | -90406.904% |
| Savara Inc. | 15.74 Million USD | 52.614% |
| Curis, Inc. | 58.35 Million USD | 87.214% |
| Daré Bioscience, Inc. | 33.6 Million USD | 77.801% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -46.51% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 72.389% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.773% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 62.581% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 98.504% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 95.144% |
| Erasca, Inc. | 141.52 Million USD | 94.728% |
| bluebird bio, Inc. | 240.23 Million USD | 96.894% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -64.812% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.573% |
| DBV Technologies S.A. | 92.16 Million USD | 91.904% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -64.812% |
| Moderna, Inc. | 6.39 Billion USD | 99.883% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 82.49% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | 48.065% |
| Molecular Templates, Inc. | 63.09 Million USD | 88.174% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 88.814% |
| Travere Therapeutics, Inc. | 472 Million USD | 98.419% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 94.794% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 87.982% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 82.814% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 96.415% |
| MacroGenics, Inc. | 217.21 Million USD | 96.565% |
| RenovoRx, Inc. | 11.39 Million USD | 34.53% |
| Adicet Bio, Inc. | 152.03 Million USD | 95.093% |
| Prime Medicine, Inc. | 186.63 Million USD | 96.002% |
| Aditxt, Inc. | 25.95 Million USD | 71.249% |
| Adagene Inc. | 41.83 Million USD | 82.164% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2.064% |
| Quantum-Si incorporated | 111.65 Million USD | 93.318% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 95.658% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | 48.819% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 79.172% |
| SciSparc Ltd. | 9.01 Million USD | 17.201% |
| Vericel Corporation | 142.04 Million USD | 94.747% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 13.812% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 67.685% |
| Generation Bio Co. | 144.46 Million USD | 94.835% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 91.014% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 91.371% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 97.477% |
| Invivyd, Inc. | 205.75 Million USD | 96.374% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 89.66% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | 20.446% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 90.086% |
| Artelo Biosciences, Inc. | 10.28 Million USD | 27.472% |
| 2seventy bio, Inc. | 289.88 Million USD | 97.426% |
| ADMA Biologics, Inc. | 66.58 Million USD | 88.795% |
| Clene Inc. | 41.07 Million USD | 81.835% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | 41.747% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 86.384% |
| GeoVax Labs, Inc. | 6.02 Million USD | -23.892% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 97.881% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 79.688% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 77.879% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 92.805% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 77.106% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 95.618% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 99.028% |
| Evaxion Biotech A/S | 22.27 Million USD | 66.498% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 94.496% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 96.824% |
| Trevena, Inc. | 38.41 Million USD | 80.577% |
| Surrozen, Inc. | 18.55 Million USD | 59.779% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 90.667% |
| Cingulate Inc. | 22.75 Million USD | 67.218% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 199.586% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 83.296% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | 9.387% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 92.725% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 99.011% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 87.98% |
| Clearmind Medicine Inc. | 8.74 Million USD | 14.647% |
| Kronos Bio, Inc. | 128.11 Million USD | 94.176% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 91.125% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -154.382% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 92.6% |
| Statera Biopharma, Inc. | 28.82 Million USD | 74.12% |
| ImmunityBio, Inc. | 362.87 Million USD | 97.944% |
| Korro Bio, Inc. | 84.53 Million USD | 91.174% |
| Kineta, Inc. | 21.15 Million USD | 64.733% |
| BioVie Inc. | 31.95 Million USD | 76.648% |
| Codexis, Inc. | 66.51 Million USD | 88.783% |
| Celularity Inc. | 215.05 Million USD | 96.531% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 96.708% |
| Celcuity Inc. | 66.23 Million USD | 88.735% |
| Virax Biolabs Group Limited | 6.54 Million USD | -13.959% |
| Cibus, Inc. | 320.3 Million USD | 97.671% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 82.649% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 77.955% |
| IN8bio, Inc. | 30.33 Million USD | 75.406% |
| Kodiak Sciences Inc. | 277.32 Million USD | 97.31% |
| Annexon, Inc. | 143.72 Million USD | 94.809% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 94.152% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 67.432% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -1065.781% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 99.043% |
| Eyenovia, Inc. | 25.4 Million USD | 70.633% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 94.683% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -34.142% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 90.572% |
| Arcellx, Inc. | 200.19 Million USD | 96.273% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 83.745% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 96.552% |
| Regulus Therapeutics Inc. | 9.95 Million USD | 25.068% |
| Moolec Science SA | 52.75 Million USD | 85.856% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 87.796% |
| Geron Corporation | 70.44 Million USD | 89.408% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 83.969% |
| Royalty Pharma plc | 862.4 Million USD | 99.135% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 92.069% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | 20.014% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 67.028% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 96.41% |
| Humacyte, Inc. | 23.49 Million USD | 68.247% |
| Structure Therapeutics Inc. | 102.77 Million USD | 92.74% |
| 89bio, Inc. | 151.2 Million USD | 95.066% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 90.689% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | 48.686% |
| Genelux Corporation | 24.33 Million USD | 69.34% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 78.006% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 95.684% |
| Notable Labs, Ltd. | 14.77 Million USD | 49.485% |
| Liquidia Corporation | 87.98 Million USD | 91.52% |
| Mustang Bio, Inc. | 48.5 Million USD | 84.617% |
| Immunovant, Inc. | 282.7 Million USD | 97.361% |
| Quantum-Si incorporated | 111.65 Million USD | 93.318% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 66.905% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 64.917% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 92.686% |
| Acasti Pharma Inc. | 11.3 Million USD | 33.979% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 67.449% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 53.309% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 83.969% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -557.6% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | 53.034% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 74.411% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 81.971% |
| PepGen Inc. | 84.76 Million USD | 91.198% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 74.82% |
| United Therapeutics Corporation | 885.1 Million USD | 99.157% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 67.415% |
| Solid Biosciences Inc. | 104.31 Million USD | 92.848% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 77.201% |
| Immuneering Corporation | 58.41 Million USD | 87.227% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -46.575% |
| Silo Pharma, Inc. | 3.92 Million USD | -90.242% |
| Belite Bio, Inc | 31.66 Million USD | 76.44% |
| XOMA Corporation | 46.46 Million USD | 83.942% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 88.955% |
| Bionomics Limited | 17.89 Billion USD | 99.958% |
| Apogee Therapeutics, Inc. | 93 Million USD | 91.978% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 120.911% |
| uniQure N.V. | 285.08 Million USD | 97.383% |
| Cassava Sciences, Inc. | 105.95 Million USD | 92.958% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2.064% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 96.158% |
| Forte Biosciences, Inc. | 32.47 Million USD | 77.027% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | 10.203% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 74.618% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -34.142% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 47.495% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | 16.065% |
| Altimmune, Inc. | 30.55 Million USD | 75.583% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 98.255% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 120.911% |
| Compugen Ltd. | 43.97 Million USD | 83.032% |
| Peak Bio, Inc. | 1249.13 USD | -597195.718% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 89.934% |
| Benitec Biopharma Inc. | 22.38 Million USD | 66.665% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 96.932% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 73.86% |
| Zura Bio Limited | 62.63 Million USD | 88.089% |
| PolyPid Ltd. | 21.04 Million USD | 64.547% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | 54.159% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 73.86% |
| Instil Bio, Inc. | 85.78 Million USD | 91.303% |
| argenx SE | 1.53 Billion USD | 99.513% |
| Immunome, Inc. | 122.82 Million USD | 93.925% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 84.608% |
| Verona Pharma plc | 67.15 Million USD | 88.889% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 71.176% |
| Shattuck Labs, Inc. | 93.61 Million USD | 92.03% |
| CervoMed Inc. | 14.95 Million USD | 50.12% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 89.447% |
| Plus Therapeutics, Inc. | 8.54 Million USD | 12.676% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 85.371% |
| Moolec Science SA | 52.75 Million USD | 85.856% |
| Enveric Biosciences, Inc. | 16.44 Million USD | 54.64% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 94.371% |
| AnaptysBio, Inc. | 181.56 Million USD | 95.891% |
| Design Therapeutics, Inc. | 78.19 Million USD | 90.458% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 91.428% |
| NeurAxis, Inc. | 8.82 Million USD | 15.42% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | 40.715% |
| Lumos Pharma, Inc. | 38.66 Million USD | 80.703% |
| Achilles Therapeutics plc | 75.25 Million USD | 90.086% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 71.176% |
| 180 Life Sciences Corp. | 13.47 Million USD | 44.641% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 71.848% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -154.382% |
| Nutriband Inc. | 5.73 Million USD | -30.118% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 93.265% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 86.594% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 85.336% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 88.712% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 86.215% |
| Palisade Bio, Inc. | 13.32 Million USD | 43.986% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 83.569% |
| Beam Therapeutics Inc. | 554.19 Million USD | 98.654% |
| Neurogene Inc. | 55.58 Million USD | 86.577% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 96.997% |
| AEON Biopharma, Inc. | 48.42 Million USD | 84.594% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 92.285% |
| Sesen Bio, Inc. | 78.38 Million USD | 90.481% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 91.068% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | 40.724% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 98.346% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 91.511% |
| Athira Pharma, Inc. | 125.46 Million USD | 94.053% |
| Vaccinex, Inc. | 23.45 Million USD | 68.19% |
| HCW Biologics Inc. | 21.02 Million USD | 64.518% |
| XOMA Corporation | 46.46 Million USD | 83.942% |
| Nektar Therapeutics | 190.9 Million USD | 96.092% |
| Arvinas, Inc. | 480 Million USD | 98.446% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -228.105% |
| Merus N.V. | 200.49 Million USD | 96.279% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 92.781% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 78.449% |
| Rezolute, Inc. | 70.38 Million USD | 89.4% |
| Clene Inc. | 41.07 Million USD | 81.835% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | 54.446% |
| BeyondSpring Inc. | 24.86 Million USD | 69.994% |
| Synlogic, Inc. | 58.53 Million USD | 87.253% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | 58.3% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -66.095% |
| Peak Bio, Inc. | 1249.13 USD | -597195.718% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 87.657% |
| Krystal Biotech, Inc. | 160.42 Million USD | 95.349% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 97.243% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 97.856% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -245.94% |
| MannKind Corporation | 125.59 Million USD | 94.06% |
| Ikena Oncology, Inc. | 84.57 Million USD | 91.178% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | 22.66% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 91.673% |
| Gossamer Bio, Inc. | 183.75 Million USD | 95.94% |
| CohBar, Inc. | 12.38 Million USD | 39.774% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 85.291% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 72.95% |
| Legend Biotech Corporation | 583.14 Million USD | 98.721% |
| Mural Oncology plc | 192.07 Million USD | 96.115% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 88.889% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 53.788% |
| Disc Medicine, Inc. | 91.12 Million USD | 91.812% |
| Champions Oncology, Inc. | 28.11 Million USD | 73.458% |
| REGENXBIO Inc. | 321.15 Million USD | 97.677% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -39.166% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 86.618% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 80.85% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 93.476% |
| Vaxart, Inc. | 90.72 Million USD | 91.776% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | 12.43% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 82.565% |
| Cellectis S.A. | 97.32 Million USD | 92.334% |
| Longeveron Inc. | 21.25 Million USD | 64.889% |
| Repare Therapeutics Inc. | 167.35 Million USD | 95.542% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.452% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 90.137% |
| Revolution Medicines, Inc. | 498.76 Million USD | 98.504% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -12.162% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 83.025% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 89.997% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 89.286% |
| Anixa Biosciences, Inc. | 11.06 Million USD | 32.541% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.844% |
| Denali Therapeutics Inc. | 527.23 Million USD | 98.585% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 13.812% |
| Veru Inc. | 101.34 Million USD | 92.638% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 68.125% |
| Cingulate Inc. | 22.75 Million USD | 67.218% |
| Passage Bio, Inc. | 108.38 Million USD | 93.116% |
| Context Therapeutics Inc. | 25.07 Million USD | 70.242% |
| Exicure, Inc. | 14.07 Million USD | 46.995% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 96.379% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 82.769% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | 18.701% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 97.045% |
| Nuvalent, Inc. | 149.49 Million USD | 95.009% |
| ABVC BioPharma, Inc. | 8.06 Million USD | 7.511% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 92.802% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 65.215% |
| OmniAb, Inc. | 83.89 Million USD | 91.107% |
| Anew Medical, Inc. | 1.3 Million USD | -473.552% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 77.228% |
| Lipocine Inc. | 15.08 Million USD | 50.524% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 89.11% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 90.202% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 81.493% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 93.503% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 66.668% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 98.877% |
| Ocugen, Inc. | 71.56 Million USD | 89.575% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 92.051% |
| Q32 Bio Inc. | 92.68 Million USD | 91.95% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 64.763% |
| Alumis Inc. Common Stock | 158.17 Million USD | 95.283% |
| Equillium, Inc. | 50.6 Million USD | 85.257% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 88.044% |
| Coya Therapeutics, Inc. | 13.9 Million USD | 46.345% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 60.451% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 84.109% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 93.121% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 39.795% |
| Dominari Holdings Inc. | 23.83 Million USD | 68.697% |
| Edesa Biotech, Inc. | 9.22 Million USD | 19.102% |
| vTv Therapeutics Inc. | 11.9 Million USD | 37.339% |
| Bio-Techne Corporation | 563.03 Million USD | 98.675% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 98.175% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 97.224% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 94.36% |
| Candel Therapeutics, Inc. | 14.41 Million USD | 48.227% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 95.442% |
| Nkarta, Inc. | 131.65 Million USD | 94.333% |
| BioCardia, Inc. | 12.12 Million USD | 38.446% |
| Iterum Therapeutics plc | 47.46 Million USD | 84.282% |